Advertisement
Advertisement
CTNM
Contineum Therapeutics, Inc. Class A Common Stock
10.56
USDSponsored
+0.26
+2.52%
Nov 10, 15:59 UTC -5
Closed
After-Market
10.55
-0.01
-0.09%
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Earnings
CTNM Earnings Reports
Positive Surprise Ratio
CTNM beat 4 of 11 last estimates.
36%
Next Report
Date of Next Report
Mar 03, 2027
Estimate for Q4 26 (Revenue/ EPS)
--
/-$0.47
Implied change from Q3 26 (Revenue/ EPS)
--
/-4.08%
Implied change from Q4 25 (Revenue/ EPS)
--
/-4.08%
Contineum Therapeutics, Inc. Class A Common Stock earnings per share and revenue
On Nov 03, 2026, CTNM reported earnings of -0.49 USD per share (EPS) for Q3 26, missing the estimate of -0.46 USD, resulting in a -5.88% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +1.03% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.47 USD, with revenue projected to reach -- USD, implying an decrease of -4.08% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kura Oncology, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.83
Actual
-$0.78
Surprise
+7.00%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Autolus Therapeutics plc - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-27.20%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
Seer, Inc. Class A Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.25
Actual
-$0.25
Surprise
+1.96%
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
TELA Bio, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.13
Surprise
+20.54%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
FAQ
What were Contineum Therapeutics, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Contineum Therapeutics, Inc. Class A Common Stock reported EPS of -$0.49, missing estimates by -5.88%, and revenue of $0.00, 0% as expectations.
How did the market react to Contineum Therapeutics, Inc. Class A Common Stock's Q3 2026 earnings?
The stock price moved up 1.03%, changed from $9.69 before the earnings release to $9.79 the day after.
When is Contineum Therapeutics, Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for Mar 03, 2027.
What are the forecasts for Contineum Therapeutics, Inc. Class A Common Stock's next earnings report?
Based on --
analysts, Contineum Therapeutics, Inc. Class A Common Stock is expected to report EPS of -$0.47 and revenue of -- for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.